Regulatory Agency's Proactive Proposal for Indication Expansion

The U.S. Food and Drug Administration (FDA) has officially proposed that AbbVie (ABBV) and other pharmaceutical companies holding approved testosterone replacement therapy (TRT) drugs discuss expanding the indication to include the treatment of low libido in patients with idiopathic hypogonadism. This initiative follows the clinical literature review conducted by the FDA Advisory Committee (AdComm) in December 2025, aiming to provide a safe hormonal treatment option for patients with low libido. Previously, patients with idiopathic hypogonadism, where the cause is unclear, faced treatment challenges. The FDA's proactive approach in opening the possibility of additional new drug application (sNDA) approval represents a significant shift in regulatory policy.

Integrating Off-Label Prescriptions into the Formal System and Ensuring Patient Safety

Existing TRT therapies have been limited to patients with well-defined pathological causes of hypogonadism, such as genetic defects or testicular damage. However, in clinical practice, off-label prescriptions have been widely used for patients with low libido due to idiopathic hypogonadism, raising concerns about misuse. By encouraging sNDA submissions, the FDA aims to incorporate this clinical reality into the formal system, formalizing off-label prescriptions as an official indication to simultaneously enhance patient safety and control drug misuse.

New Growth Momentum for the $2 Billion TRT Market

The global TRT market is currently valued at approximately $2 billion (USD 2.0B) as of 2025, with a moderate annual growth rate of 3-5%. If an official indication for the treatment of low libido in patients with idiopathic hypogonadism is added, the potential patient population will expand significantly, and the market size is projected to grow rapidly to over $3 billion by the mid-2030s. For pharmaceutical companies, this represents a strong financial opportunity to defend against patent expiration risks and extend the life cycle of existing products.

Strengthening Portfolios and Competitive Landscape Among Major Developers

With this regulatory change, major TRT developers, including AbbVie (ABBV) with AndroGel, Halozyme Therapeutics (HALO) with Xyosted, and Lipocine (LPCN) with Tlando, are likely to benefit. In particular, competition is expected to intensify with emerging pharmaceutical companies offering more convenient oral testosterone therapies, such as Jatenzo (Tolmar Pharmaceuticals) and Kyzatrex (Marius Pharmaceuticals). Pharmaceutical companies will need to initiate the design of additional clinical trials to secure the safety data required by the FDA, which will be more advantageous for leading companies with strong R&D and regulatory risk management capabilities.

Final Recommendations for Investors and Industry Stakeholders

From an investor perspective, it is important to carefully assess how quickly each pharmaceutical company responds to the FDA's sNDA submission request and the impact of additional clinical trial costs on its financial position. While this indication expansion may increase clinical costs in the short term, it is expected to have a positive impact on corporate value in the medium to long term by expanding the prescription base. However, it is important to remember that testosterone therapies are still classified as Schedule III controlled substances due to concerns about cardiovascular side effects, and companies that can overcome the safety hurdle will ultimately be the winners.